Cargando…
Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France
Linezolid is one of the most effective drugs for treating multidrug-resistant tuberculosis (MDR TB), but adverse effects remain problematic. We evaluated 57 MDR TB patients who had received >1 dose of linezolid during 2011–2016. Overall, patients received 600 mg/day of linezolid for a median of 1...
Autores principales: | Jaspard, Marie, Butel, Nathalie, El Helali, Najoua, Marigot-Outtandy, Dhiba, Guillot, Helene, Peytavin, Gilles, Veziris, Nicolas, Bodaghi, Bahram, Flandre, Philippe, Petitjean, Gregoire, Caumes, Eric, Pourcher, Valerie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392460/ https://www.ncbi.nlm.nih.gov/pubmed/32687026 http://dx.doi.org/10.3201/eid2608.191499 |
Ejemplares similares
-
Clinical Features and Outcome of Multidrug-Resistant Osteoarticular Tuberculosis: A 12-Year Case Series from France
por: Bonnet, Isabelle, et al.
Publicado: (2022) -
Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman
por: Jaspard, Marie, et al.
Publicado: (2017) -
Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?
por: Grard, Soazic, et al.
Publicado: (2015) -
Low Rate of Acquired Linezolid Resistance in Multidrug-Resistant Tuberculosis Treated With Bedaquiline-Linezolid Combination
por: Du, Jian, et al.
Publicado: (2021) -
Corynebacterium striatum thrombophlebitis: a nosocomial multidrug-resistant disease?
por: Tang, Julie, et al.
Publicado: (2021)